Literature DB >> 11570600

Phenotypic and neuropathologic heterogeneity of anti-Hu antibody-related paraneoplastic syndrome presenting with progressive dysautonomia: report of two cases.

A S Winkler1, A Dean, M Hu, N Gregson, K R Chaudhuri.   

Abstract

The anti-Hu antibody (HuAb) is directed against RNA-associated neuronal proteins and is known to cause paraneoplastic encephalomyelitis/sensory neuronopathy syndrome mostly when associated with small cell lung cancer (SCLC). Paraneoplastic encephalomyelitis/sensory neuronopathy syndrome with concurrent autonomic neuropathy has been reported to occur in paraneoplastic syndromes, although its occurrence concomitant with acute pandysautonomia is less frequent. The authors describe the clinical, neuropathologic, and serologic features of two cases with an anti-Hu-related paraneoplastic syndrome presenting with progressive autonomic neuropathy. Both patients showed features of dysautonomia, including postural dizziness, abdominal pain, and diarrhea, and symptoms of sensory neuropathy. Investigations disclosed severe sensory and autonomic neuropathy and positive HuAb titers. The disease of patient 1 had a very rapid progression, and the patient died of cardiac arrest within 2 months of the onset of symptoms. The autopsy revealed SCLC. In contrast, the disease of patient 2 had a less aggressive course. An extensive tumor search disclosed SCLC only 28 months after onset of symptoms, and the patient died 1 month later of cardiorespiratory arrest. Autopsies in both cases showed inflammation involving the intermediolateral columns and the dorsal root ganglia. These two cases illustrate the association of early dysautonomia with HuAb-related paraneoplastic syndrome and the variations of clinical, neuropathologic, and serologic findings in these types of cases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11570600     DOI: 10.1007/bf02322055

Source DB:  PubMed          Journal:  Clin Auton Res        ISSN: 0959-9851            Impact factor:   4.435


  10 in total

1.  Anti-Hu--associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients.

Authors:  J Dalmau; F Graus; M K Rosenblum; J B Posner
Journal:  Medicine (Baltimore)       Date:  1992-03       Impact factor: 1.889

2.  Tissue distribution of pathological lesions and Hu antigen expression in paraneoplastic sensory neuronopathy.

Authors:  M Ichimura; M Yamamoto; Y Kobayashi; O Kawakami; Y Niimi; N Hattori; M Nagamatsu; Y Hashizume; G Sobue
Journal:  Acta Neuropathol       Date:  1998-06       Impact factor: 17.088

Review 3.  Paraneoplastic encephalomyelitis: an update of the effects of the anti-Hu immune response on the nervous system and tumour.

Authors:  R D Voltz; J B Posner; J Dalmau; F Graus
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-08       Impact factor: 10.154

4.  Association of small cell lung cancer and the anti-Hu paraneoplastic syndrome: radiographic and CT findings.

Authors:  C Chartrand-Lefebvre; N Howarth; P Grenier; F Keime; B Orcel; C Beigelman
Journal:  AJR Am J Roentgenol       Date:  1998-06       Impact factor: 3.959

5.  Expression of Hel-N1 and Hel-N2 in small-cell lung carcinoma.

Authors:  P H King; E J Dropcho
Journal:  Ann Neurol       Date:  1996-05       Impact factor: 10.422

Review 6.  Paraneoplasia and autoimmunologic injury of the nervous system: the anti-Hu syndrome.

Authors:  M K Rosenblum
Journal:  Brain Pathol       Date:  1993-07       Impact factor: 6.508

7.  Hu antigens: reactivity with Hu antibodies, tumor expression, and major immunogenic sites.

Authors:  G T Manley; P S Smitt; J Dalmau; J B Posner
Journal:  Ann Neurol       Date:  1995-07       Impact factor: 10.422

8.  Enteric neuronal autoantibodies in pseudoobstruction with small-cell lung carcinoma.

Authors:  V A Lennon; D F Sas; M F Busk; B Scheithauer; J R Malagelada; M Camilleri; L J Miller
Journal:  Gastroenterology       Date:  1991-01       Impact factor: 22.682

9.  Indolent anti-Hu-associated paraneoplastic sensory neuropathy.

Authors:  F Graus; I Bonaventura; M Uchuya; J Valls-Solé; R Reñé; J M Leger; E Tolosa; J Y Delattre
Journal:  Neurology       Date:  1994-12       Impact factor: 9.910

10.  Neuronal nicotinic ACh receptor antibody in subacute autonomic neuropathy and cancer-related syndromes.

Authors:  S Vernino; J Adamski; T J Kryzer; R D Fealey; V A Lennon
Journal:  Neurology       Date:  1998-06       Impact factor: 9.910

  10 in total
  6 in total

Review 1.  The clinical approach to autonomic failure in neurological disorders.

Authors:  Eduardo E Benarroch
Journal:  Nat Rev Neurol       Date:  2014-05-27       Impact factor: 42.937

2.  Acute pandysautonomia--restitutio ad integrum by high prednisolone therapy.

Authors:  Walter Struhal; Stephanie Hödl; Samy Mazhar; Gerhard Ransmayr
Journal:  Wien Klin Wochenschr       Date:  2011-07-25       Impact factor: 1.704

3.  Fludeoxyglucose positron emission tomography-computed tomography in limbic encephalitis.

Authors:  Sushanti Patil; Vikram Lele
Journal:  Indian J Nucl Med       Date:  2014-10

Review 4.  Diagnosis and management of gastrointestinal complications in adult cancer patients: 2017 updated evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).

Authors:  M Schmidt-Hieber; J Bierwirth; D Buchheidt; O A Cornely; M Hentrich; G Maschmeyer; E Schalk; J J Vehreschild; Maria J G T Vehreschild
Journal:  Ann Hematol       Date:  2017-11-24       Impact factor: 3.673

Review 5.  Pain as a First Manifestation of Paraneoplastic Neuropathies: A Systematic Review and Meta-Analysis.

Authors:  Panagiotis Zis; Antonella Paladini; Alba Piroli; Patrick C McHugh; Giustino Varrassi; Marios Hadjivassiliou
Journal:  Pain Ther       Date:  2017-07-01

6.  Integrated treatment for autonomic paraneoplastic syndrome improves performance status in a patient with small lung cell carcinoma: a case report.

Authors:  Tatsuya Ueno; Yukihiro Hasegawa; Rie Hagiwara; Tomoya Kon; Jin-Ichi Nunomura; Masahiko Tomiyama
Journal:  BMC Neurol       Date:  2018-11-10       Impact factor: 2.474

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.